Heterogeneous genetic and non-genetic mechanisms contribute to response and resistance to azacitidine monotherapy.

Symeonidou, Vasiliki; Metzner, Marlen; Usukhbayar, Batchimeg; Jackson, Aimee E; Fox, Sonia; Craddock, Charles F; Vyas, Paresh.

Afiliação

Symeonidou V; MRC Molecular Haematology Unit, Oxford Biomedical Research Centre Haematology Theme, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine University of Oxford Oxford UK.
Metzner M; MRC Molecular Haematology Unit, Oxford Biomedical Research Centre Haematology Theme, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine University of Oxford Oxford UK.
Usukhbayar B; MRC Molecular Haematology Unit, Oxford Biomedical Research Centre Haematology Theme, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine University of Oxford Oxford UK.
Jackson AE; Cancer Research UK Clinical Trials Unit University of Birmingham Birmingham UK.
Fox S; Centre for Clinical Haematology Queen Elizabeth Hospital Birmingham UK.
Craddock CF; Centre for Clinical Haematology Queen Elizabeth Hospital Birmingham UK.
Vyas P; MRC Molecular Haematology Unit, Oxford Biomedical Research Centre Haematology Theme, Oxford Centre for Haematology, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine University of Oxford Oxford UK.

EJHaem ; 3(3): 794-803, 2022 Aug.

Article em En | MEDLINE | ID: mdl-36051087